Mobile

A 4-week double-blind, placebo-controlled, randomised, parallel group phase IIa study to assess the tolerability/safety and efficacy of inhaled AZD4818 in patients with moderate to severe Chronic Obst...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-003962-16

A 4-week double-blind, placebo-controlled, randomised, parallel group phase IIa study to assess the tolerability/safety and efficacy of inhaled AZD4818 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate the tolerability and safety of inhaled AZD4818 delivered via a dry powder inhaler, Turbuhaler®, in COPD patients by assessment of: . incidence and nature of adverse events (AE) . Electro Cardio Graphic (ECG) parameters, vital signs, and laboratory assessments (clinical chemistry, haematology, and urin analysis parameters).

Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)

Liens